AIDS Treatment News logo      

June 29, 2010

Rosiglitazone Revisited: An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality

Arch Intern Med: "Conclusions -- Eleven years after the introduction of rosiglitazone, the totality of randomized clinical trials continue to demonstrate increased risk for MI although not for CV or all-cause mortality. The current findings suggest an unfavorable benefit to risk ratio for rosiglitazone."

Comments: This study was not HIV-related. The FDA is considering whether this diabetes drug will stay on the U.S. market.